Vivani's NPM 139, a miniature under the skin device designed to release semaglutide for roughly six months, enters phase 1 in coming weeks, with Novo choosing not to lock up the platform.
Novo Nordisk has signed a non-exclusive deal to test a miniature under-the-skin implant that would release semaglutide, the active ingredient in its weight-loss drug Wegovy, for roughly six months at a time, as the GLP-1 arms race pivots from molecule to delivery format. The agreement with Vivani Medical covers NPM-139, a device built on Vivani's NanoPortal platform, and is set to enter a phase 1 first-in-human study in the coming weeks with Wegovy injections as the active comparator. Financial terms were not disclosed.
The deal's structure matters more than the device. By choosing a non-exclusive arrangement, Novo has avoided locking up Vivani's implant platform the way a traditional licensing deal would. The joint statement re-reported by FierceBiotech and the press release syndicated through GlobeNewswire both state there are no exclusivity provisions for Novo, leaving Vivani's NanoPortal platform unencumbered. For a dominant incumbent facing credible competition, that is a tell: the GLP-1 war is being fought less over a single molecule and more over the format in which that molecule reaches a patient, and Novo is choosing optionality over commitment.
The competitive backdrop explains the urgency. Eli Lilly has built a parallel franchise around tirzepatide, with Mounjaro (for Type 2 diabetes) and Zepbound (for weight management) already on the market and a third candidate, Foundayo, advancing through the pipeline. Each of those drugs is itself a weekly injection, but Lilly's broader commercial machinery and pricing pressure have narrowed Novo's lead and made patient retention (adherence, persistence, the option to stop treatment cleanly) a more central variable. A twice-yearly implant, if it works as designed, would change the patient-experience question rather than the efficacy one. Vivani CEO Adam Mendelsohn framed the device as targeting "a growing segment of patients who would prefer a convenient once- or twice-yearly treatment option and the peace of mind that treatment could be stopped at any time if that became necessary," per the press release circulated via GlobeNewswire. That phrasing captures the design intent; it is not a clinical claim.
NPM-139 is built on Vivani's biodegradable NanoPortal implant technology, which is designed to deliver a sustained peptide payload over multi-month intervals after a brief in-office insertion. Vivani reported positive preclinical weight-loss data for NPM-139 in March 2025, the most recent public benchmark on the program before the Novo agreement. The phase 1 study starting in coming weeks is the first time the device will be tested in people for chronic weight management, with Wegovy injections as the active comparator. As of Vivani's Q1 2026 financial results and business update, the implant portfolio remains early-stage, and the company's FY2025 10-K filing frames the broader pipeline as investigational. A subdermal GLP-1 implant has theoretical compliance advantages (no weekly self-injection, easier persistence) and real-world trade-offs (insertion and removal visits, foreign-body tolerability, dose-titration inflexibility).
What to watch: the phase 1 readout, expected in the months after enrollment; Vivani's cash runway as the program advances; the LIBERATE-1 trial of an exenatide-based implant from the same NanoPortal family, which has already achieved first implant and full enrollment and could validate the platform's clinical readiness in parallel; and whether Vivani signs a second partner for NPM-139. If Vivani does add a second GLP-1 partner, it will be the strongest signal yet that Novo's optionality play is, in fact, how the GLP-1 war now gets fought.